<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01613573</url>
  </required_header>
  <id_info>
    <org_study_id>GenSci-004 Clinical Trial</org_study_id>
    <nct_id>NCT01613573</nct_id>
  </id_info>
  <brief_title>Crossover Study to Assess the Safety and Pharmacokinetic of Pegylated Somatropin(PEG Somatropin) in GHD Children</brief_title>
  <acronym>Phase 1</acronym>
  <official_title>A Phase 1, Open-Label, Single and Multiple Dose Study to Assess the Safety and Pharmacokinetics of Pegylated Somatropin(PEG Somatropin) in GHD Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GeneScience Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>GeneScience Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the phase 1 study is to assess the safety and pharmacokinetics of PEG
      somatropin, which administered once per week, compared with the daily used somatropin, and to
      evaluate the safety and possibility to replace daily used somatropin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pharmacokinetics parameter</measure>
    <time_frame>Somatropin AQ: predose(0),1,2,3,4,6,8,10,12,16,20,24 hours post-dose. PEG somatropin: predose (0),2,4,8,12,18,24,36,48,72,96,120,144,168 hours post-dose</time_frame>
    <description>Cmax, AUC during the time interval for the first dose and last dose, Half-Life(t1/2), Apparent body clearance(CL), Mean residence time(MRT),steady-state volume of distribution(Vss)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IGF-1, IGFBP-3</measure>
    <time_frame>Day I to Day 7 in each treatment period (33 time points) for daily used somatropin, Day I to Day 42 in each treatment period (35 time points) for PEG somatropin</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">12</enrollment>
  <condition>Growth Hormone Deficiency</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>somatropin AQ</intervention_name>
    <description>somatropin injection 0.2mg/kg/w once per day, inject for 7 continuous days 4 weeks for cleaning period</description>
    <other_name>Somatropin injection</other_name>
    <other_name>rhGH</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated somatropin</intervention_name>
    <description>Pegylated somatropin 0.2mg/kg/w once per week, for continuous 6 weeks Subcutaneous injection</description>
    <other_name>PEG somatropin</other_name>
    <other_name>PEG GH</other_name>
    <other_name>pharmacokinetics</other_name>
    <other_name>growth hormone deficiency</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  have a height less than two standard deviations (SD) below the median height for
             individuals of the same age or height, a growth velocity (GV) ≤4 cm/yr, a GH peak
             concentration &lt;7 ng/ml in two different provocative tests, a bone age (BA; ≤9 years in
             girls and ≤10 years in boys) at least 2 years less than his/her chronological age
             (CA);be in preadolescence (Tanner stage 1) and have a CA &gt;3 years;have a height value
             recorded 3 months before the start of GH treatment to calculate pre-treatment GV;
             receive no prior GH treatment or stop the GH treatment for more than 4 weeks;sign
             informed consent

        Exclusion Criteria:

          -  Patients with Liver and kidney dysfunction (ALT&gt; upper limit of normal 2 times, Cr&gt;
             upper limit of normal), hepatitis B virus detection, antigen-HBc, HBsAg and HBeAg are
             positive

          -  patients with known to a highly allergic constitution or allergic to the drug of this
             study

          -  Patients with diabetes, serious cardiopulmonary, blood system, malignant tumor and
             other diseases or systemic infection in immunocompromised and mental diseases

          -  Patients with other growth disorders, such as Turner syndrome, constitutional delay of
             growth and puberty, Laron syndrome, GH receptor deficiency, girls with growth delay
             have not ruled out chromosomal abnormalities

          -  Participated in clinical trials of other drugs in 3 months

          -  Other cases that the researchers considered unsuitable for this clinical trial
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luo Xiaoping, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tongji Hospital</affiliation>
  </overall_official>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2012</study_first_submitted>
  <study_first_submitted_qc>June 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2012</study_first_posted>
  <last_update_submitted>June 13, 2012</last_update_submitted>
  <last_update_submitted_qc>June 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pegylated Somatropin</keyword>
  <keyword>PEG-GH</keyword>
  <keyword>Phase 1 study</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dwarfism, Pituitary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

